Published in J Infect Dis on March 15, 2008
Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun (2009) 3.38
A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS Pathog (2009) 2.09
Development of an acute and highly pathogenic nonhuman primate model of Nipah virus infection. PLoS One (2010) 1.54
Maturation Pathways of Cross-Reactive HIV-1 Neutralizing Antibodies. Viruses (2009) 1.54
A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge. Sci Transl Med (2011) 1.35
Basic research in HIV vaccinology is hampered by reductionist thinking. Front Immunol (2012) 1.33
Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets. J Virol (2014) 1.26
A novel model of lethal Hendra virus infection in African green monkeys and the effectiveness of ribavirin treatment. J Virol (2010) 1.21
Evidence for henipavirus spillover into human populations in Africa. Nat Commun (2014) 1.08
Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody. Sci Transl Med (2014) 1.02
A treatment for and vaccine against the deadly Hendra and Nipah viruses. Antiviral Res (2013) 1.02
Henipavirus outbreaks to antivirals: the current status of potential therapeutics. Curr Opin Virol (2012) 0.98
Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses. Expert Opin Biol Ther (2009) 0.98
Human monoclonal antibody fragments binding to insulin-like growth factors I and II with picomolar affinity. Mol Cancer Ther (2011) 0.94
Targeting of bone-derived insulin-like growth factor-II by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment. Clin Cancer Res (2009) 0.91
Emerging paramyxoviruses: molecular mechanisms and antiviral strategies. Expert Rev Mol Med (2011) 0.90
Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains. J Virol (2013) 0.87
Henipavirus mediated membrane fusion, virus entry and targeted therapeutics. Viruses (2012) 0.87
Engineered single human CD4 domains as potent HIV-1 inhibitors and components of vaccine immunogens. J Virol (2011) 0.86
A functional henipavirus envelope glycoprotein pseudotyped lentivirus assay system. Virol J (2010) 0.86
Use of monoclonal antibodies against Hendra and Nipah viruses in an antigen capture ELISA. Virol J (2010) 0.86
Hendra and nipah infection: pathology, models and potential therapies. Infect Disord Drug Targets (2011) 0.84
Immunization strategies against henipaviruses. Curr Top Microbiol Immunol (2012) 0.83
Crystal structure of the Hendra virus attachment G glycoprotein bound to a potent cross-reactive neutralizing human monoclonal antibody. PLoS Pathog (2013) 0.83
An Outdated Notion of Antibody Specificity is One of the Major Detrimental Assumptions of the Structure-Based Reverse Vaccinology Paradigm, Which Prevented It from Helping to Develop an Effective HIV-1 Vaccine. Front Immunol (2014) 0.82
Interactions of human complement with virus particles containing the Nipah virus glycoproteins. J Virol (2011) 0.82
Ephrin-B2 and ephrin-B3 as functional henipavirus receptors. Semin Cell Dev Biol (2011) 0.81
A recombinant Hendra virus G glycoprotein subunit vaccine protects nonhuman primates against Hendra virus challenge. J Virol (2014) 0.81
Long-lasting protective antiviral immunity induced by passive immunotherapies requires both neutralizing and effector functions of the administered monoclonal antibody. J Virol (2010) 0.80
Novel Functions of Hendra Virus G N-Glycans and Comparisons to Nipah Virus. J Virol (2015) 0.80
Hendra virus. Vet Clin North Am Equine Pract (2014) 0.80
Viral antibody dynamics in a chiropteran host. J Anim Ecol (2013) 0.79
Detailed morphological characterisation of Hendra virus infection of different cell types using super-resolution and conventional imaging. Virol J (2014) 0.78
Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines. Emerg Microbes Infect (2012) 0.77
Hendra virus and Nipah virus animal vaccines. Vaccine (2016) 0.75
Escape From Monoclonal Antibody Neutralization Affects Henipavirus Fitness In Vitro and In Vivo. J Infect Dis (2015) 0.75
Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases. Expert Rev Anti Infect Ther (2015) 0.75
Containing the contagion: treating the virus that inspired the film. Sci Transl Med (2011) 0.75
Bats are natural reservoirs of SARS-like coronaviruses. Science (2005) 13.44
Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature (2007) 11.73
Evaluation of gene expression measurements from commercial microarray platforms. Nucleic Acids Res (2003) 8.08
Structure of a V3-containing HIV-1 gp120 core. Science (2005) 7.69
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol (2011) 5.43
Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc Natl Acad Sci U S A (2004) 5.15
Experimental observation of the quantum anomalous Hall effect in a magnetic topological insulator. Science (2013) 4.69
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol (2003) 4.49
Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science (2009) 4.20
NETWORK EXPLORATION VIA THE ADAPTIVE LASSO AND SCAD PENALTIES. Ann Appl Stat (2009) 3.91
Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun (2009) 3.38
Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature (2013) 3.27
Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. Proc Natl Acad Sci U S A (2005) 3.18
Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature (2013) 3.14
Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci U S A (2002) 3.08
Hendra and Nipah viruses: different and dangerous. Nat Rev Microbiol (2006) 2.95
Nonparametric Independence Screening in Sparse Ultra-High Dimensional Additive Models. J Am Stat Assoc (2011) 2.89
A previously unknown reovirus of bat origin is associated with an acute respiratory disease in humans. Proc Natl Acad Sci U S A (2007) 2.88
Improved rapid amplification of cDNA ends (RACE) for mapping both the 5' and 3' terminal sequences of paramyxovirus genomes. J Virol Methods (2005) 2.66
Evidence of henipavirus infection in West African fruit bats. PLoS One (2008) 2.53
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood (2012) 2.52
Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology (2008) 2.37
Comparative analysis of bat genomes provides insight into the evolution of flight and immunity. Science (2012) 2.29
Antibodies to SARS coronavirus in civets. Emerg Infect Dis (2004) 2.27
The SARS-CoV S glycoprotein: expression and functional characterization. Biochem Biophys Res Commun (2003) 2.23
A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS Pathog (2009) 2.09
Host cell recognition by the henipaviruses: crystal structures of the Nipah G attachment glycoprotein and its complex with ephrin-B3. Proc Natl Acad Sci U S A (2008) 2.08
Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope. Biochemistry (2004) 2.01
Thiol/disulfide exchange is a prerequisite for CXCR4-tropic HIV-1 envelope-mediated T-cell fusion during viral entry. Blood (2003) 2.00
Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. J Virol (2006) 2.00
Neutralization assays for differential henipavirus serology using Bio-Plex protein array systems. J Virol Methods (2007) 1.99
Long-term survival of an urban fruit bat seropositive for Ebola and Lagos bat viruses. PLoS One (2010) 1.95
Bats and their virome: an important source of emerging viruses capable of infecting humans. Curr Opin Virol (2012) 1.91
Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. J Biol Chem (2006) 1.90
Durable protection from Herpes Simplex Virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene. Cell Host Microbe (2009) 1.90
Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus. J Virol (2005) 1.89
Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library. J Immunol Methods (2003) 1.87
Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine. J Virol (2006) 1.87
Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J Clin Invest (2005) 1.82
Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. J Virol (2004) 1.80
Pteropid bats are confirmed as the reservoir hosts of henipaviruses: a comprehensive experimental study of virus transmission. Am J Trop Med Hyg (2011) 1.80
Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates. J Virol (2002) 1.79
Regulation of human immunodeficiency virus type 1 envelope glycoprotein fusion by a membrane-interactive domain in the gp41 cytoplasmic tail. J Virol (2005) 1.76
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A (2007) 1.76
Filamin-A regulates actin-dependent clustering of HIV receptors. Nat Cell Biol (2007) 1.71
Membrane fusion tropism and heterotypic functional activities of the Nipah virus and Hendra virus envelope glycoproteins. J Virol (2002) 1.69
Vertical transmission and fetal replication of Nipah virus in an experimentally infected cat. J Infect Dis (2007) 1.68
Cedar virus: a novel Henipavirus isolated from Australian bats. PLoS Pathog (2012) 1.68
Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma. J Clin Oncol (2013) 1.67
Local quasi-likelihood with a parametric guide. Ann Stat (2009) 1.65
Ebola virus antibodies in fruit bats, Ghana, West Africa. Emerg Infect Dis (2012) 1.62